Welcome to the SACT Systemic Anti-Cancer Therapy Dataset website

The Systemic Anti-Cancer Therapy dataset is the national mandatory collection of systemic anti-cancer therapy activity from all NHS England chemotherapy providers. This website contains all the latest information available from the SACT department within the National Cancer Registration and Analysis service of Public Health England

Upload feature panel Top Regimen feature panel

SACT is an important initiative with a wide range of benefits.

It has been designed to:

- provide a clear picture of patterns of systemic anti-cancer therapy, including chemotherapy, being given across England.

- support patients and their clinical teams in choosing appropriate treatments and care.

- understand patterns of service provision and support rational clinical decision making to improve patient care.

The Scope of SACT

The SACT dataset collects information reported routinely by NHS trusts on the treatment of malignant disease in secondary care in England.  This database relates to all cancer patients, both adult and paediatric, in acute inpatient, day-case and outpatient settings and delivery in the community. It covers systemic anti-cancer treatment for all solid and haematological malignancies, including patients in clinical trials.

Systemic anti-cancer therapies, including chemotherapy, have been provided in the NHS for decades but no national recording of treatment has previously existed. Systemic anti-cancer therapies are increasingly successful as a treatment but are ever more complex and expense. Accurate, timely and complete data collection is a priority and supported through electronic clinical data collection.

The SACT data collection is the world’s first comprehensive database, collecting information on systemic-anti cancer therapies on a national scale. It provides a powerful new tool to understand patterns of service provision and support clinical decision making to improve patient care. The data set has been designed to understand outcomes of systemic treatments and by linking it to other data sources, Public Health England can provide a complete picture of the cancer patient pathway.


SACT data improvement areas for the NHS England MO CQUIN

The NHS England medicines optimisation CQUIN encompasses SACT data improvement requirements, which have recently been published.

 Trusts not signed up to the CQUIN can still benefit from reviewing and where necessary improving their data because these targets will form part of the standard contract in the 2018/2019 financial year.

 The SACT data improvement areas encompassed in the Medicines Optimisation CQUIN have been developed by the SACT team in partnership with NHS England.

 The documents below, which have been circulated to commissioning hubs and registered SACT contacts at NHS trusts, provide guidance and data to support the required SACT data improvement.

Data improvement requirements

The MO CQUIN SACT data improvement guidance document provides detailed information on the requirements, timeframes, suggested improvements and targets across six data improvement areas.

SACT data compliance reports

The data compliance reports provide trust data relevant to the CQUIN requirements. Included in them are summary data for the trust and data split age, diagnostic group and in some cases month of upload.

Trust data is  presented alongside the national average in the baseline period (Jan – March 2017) and the CQUIN targets.

These reports will be updated at the end of each quarter.

1. SACT data compliance report – up to March 2017

2. SACT data compliance report – up to June 2017

3. SACT data compliance report – up to September 2017

 The PHE SACT team will provide support and information where possible to help trusts make these improvements, contact SACT@phe.gov.uk if you have any questions.

PHE data briefing - 30 Day Mortality

Public Health England (PHE) is pleased to announce the publishing of a report on trust-level 30–day mortality after systemic anticancer therapy for breast and lung cancer in England for 2014 using SACT data.

This follows the publication of a paper in the journal The Lancet Oncology written by PHE and Cancer Research UK on 30-day mortality following chemotherapy on patients with breast and non-small cell lung cancer treated in England in 2014.



The SACT 30-day mortality workbook for the report is also available under briefings on this page. This workbook shows the position on the 30-day mortality funnel plots for all trusts submitting SACT data for patients with breast and lung cancer in England during 2014.